Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Orange, California and other locations
Dates
study started
estimated completion

Description

Summary

The purpose of this study is to determine whether BMS-986288 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of select advanced solid tumors.

Official Title

A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Malignant Tumors

Keywords

Advanced Cancer, Nivolumab, BMS-986288, Regorafenib, BMS-986288 Monotherapy

Eligibility

You can join if…

Open to people ages 18 years and up

  • Histologic or cytologic confirmation of select solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease and have at least 1 lesion accessible for biopsy
  • Eastern Cooperative Oncology Group Performance Status of 0 or 1
  • Received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to select solid tumor histologies

You CAN'T join if...

  • Active, known or suspected autoimmune disease
  • Active malignancy requiring concurrent intervention
  • Primary Central Nervous System (CNS) malignancies or tumors with CNS metastasis as the only site of disease, will be excluded

    Other protocol-defined inclusion/exclusion criteria apply

Locations

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center not yet accepting patients
    Orange California 92868 United States
  • University Of Colorado accepting new patients
    Aurora Colorado 80045 United States

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Bristol-Myers Squibb
Links
BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting FDA Safety Alerts and Recalls Investigator Inquiry Form
ID
NCT03994601
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 494 study participants
Last Updated